Meeting
2023 ASCO Annual Meeting
Geographical and baseline clinical characteristics of participants enrolled in hepatocellular carcinoma (HCC) trials: Analysis of US FDA approvals.
Authors
M. Naomi Horiba
FDA, Silver Spring, MD
M. Naomi Horiba , Shruti U. Gandhy , Sandra J. Casak , Steven Lemery , Paul Kluetz , Richard Pazdur , Lola A. Fashoyin-Aje
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer - Advanced/Metastatic Disease
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4115)
DOI
10.1200/JCO.2023.41.16_suppl.4115
Abstract #
4115
Poster Bd #
436
Abstract Disclosures
Similar Posters
Poster
2019 Gastrointestinal Cancers Symposium
Real world eligibility for cabozantinib (C), regorafenib (Reg), and ramucirumab (Ram) in hepatocellular carcinoma (HCC) patients after sorafenib (S).
First Author: Andrea S. Fung
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Presence and impact of antidrug antibodies (ADAs) to tremelimumab (T) or durvalumab (D) in the phase 3 HIMALAYA study of unresectable hepatocellular carcinoma (uHCC).
First Author: Oxana V. Crysler
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Real world data of systemic therapy for hepatocellular carcinoma in Japan: HERITAGE study.
First Author: Yoshinari Asaoka
Poster
2020 ASCO Virtual Scientific Program
Clinical value of atezolizumab + bevacizumab for first-line unresectable hepatocellular carcinoma (HCC): A network meta-analysis.
First Author: Arndt Vogel